Profile:
Jazz Pharmaceuticals, Inc.
3180 Porter Drive
Palo Alto, CA 94304
United States - Map
Phone: 650-496-3777
Fax: 650-496-3781
Web Site: http://www.jazzpharmaceuticals.com
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 216
BUSINESS SUMMARY
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia. The company's other product candidates in clinical development comprises JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7 for the treatment of restless legs syndrome. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California.
Market Pulse
Jun 10, 2009, 12:17 p.m. EST
Jazz Pharma rockets ahead of data release...
BOSTON (MarketWatch) -- Shares of Jazz Pharmaceuticals rocketed over 209% on Wednesday ahead of the scheduled release of Phase III clinical data for its fibromyalgia treatment candidate sodium oxybate, or JZP-6. Jazz plans to present various data on June 10, 11 and 12 at two scientific meetings. Jazz added it hopes to file for U.S. approval of the product by the end of 2009. Shares of the biotech group were up 163% at $2.68 in midday trading. Sodium oxybate is already approved in the U.S. for the treatment of various sleep disorders.
Busted through the 200-day MA on a Runaway Gap Up.
Runaway gaps are also called measuring gaps, and are best described as gaps that are caused by increased interest in the stock. For runaway gaps to the upside, it usually represents traders who did not get in during the initial move of the up trend and while waiting for a retracement in price, decided it was not going to happen. Increased buying interest happens all of a sudden, and the price gaps above the previous day's close. This type of runaway gap represents an almost panic state in traders. Also, a good uptrend can have runaway gaps caused by significant news events that cause new interest in the stock. In the chart below, note the significant increase in volume during and after the runaway gap.
Runaway gaps can also happen in downtrends. This usually represents increased liquidation of that stock by traders and buyers who are standing on the sidelines. These can become very serious as those who are holding onto the stock will eventually panic and sell – but sell to whom? The price has to continue to drop and gap down to find buyers. Not a good situation.
The term measuring gap is also used for runaway gaps. This is an interpretation that is hard to find examples for, but it is a way of helping one decide how much longer a trend will last. The theory is that the measuring gap will occur in the middle, or half way, through the move.
Sometimes, the futures market will have runaway gaps that are caused by trading limits imposed by the exchanges. Getting caught on the wrong side of the trend when you have these limit moves in futures can be horrifying. The good news is that you can also be on the right side of them. These are not common occurrences in the futures market despite all the wrong information being touted by those who do not understand it, and are only repeating something they read from an uninformed reporter.
52wk Range: 0.52 - 8.95
Volume: 18,442,117
Avg Vol (3m): 57,210.8
Technicals
Most Actives
Gap Up
Percentage Gainer
Last Price Quote is:
225.34%above 13-day MA
250.18%above 50-day MA
RS Rating: 97
Fundamentals
Key Data:
Market Cap (M): $29.21
P/E Ratio: N/A
PEG Ratio: N/A
Next Earnings: 08/06/2009
Last Analyst Rating: Sell
Jazz it on up....... 8)
UPDATE 1-Jazz Pharma pain drug meets late-stage study main goal
Wed Jun 24, 2009 5:22pm EDT
* Says results were highly statistically significant
* Says submitting NDA for fibr1omyalgia by end of '09
* Says partner to consult EMEA for path forward
* Shares jump 41 percent
June 24 (Reuters) - Jazz Pharmaceuticals Inc (JAZZ.O) said preliminary data from a second late-stage trial of its experimental pain drug Xyrem, showed that the study met its main goal, sending its shares up 41 percent.
The company, which already markets the drug as a treatment for sleep disorder, said patients treated with Xyrem showed a decrease of 30 percent or more in pain and fatigue.
Jazz said it expects to file for marketing approval of the drug for fibromyalgia with the U.S. health regulator, while its Belgian partner UCB group (UCB.BR) would consult with the European Medicines Agency to define the path forward.
Shares of the company, which have nearly tripled in the last three months, jumped to a high of $4.59 after the bell. They closed at $3.25 Wednesday on Nasdaq.
Jazz shares rise on pain disorder treatment study...
Jazz Pharmaceuticals shares rise on positive study data for pain disorder patients
On Thursday June 25, 2009, 10:44 am EDT
NEW YORK (AP) -- Shares of Jazz Pharmaceuticals Inc. skyrocketed Thursday after the company said its experimental pain disorder drug met key goals in reducing pain in fibromyalgia patients.
The late-stage study results confirm prior late-stage data for JZP-6, which contains the same active ingredient found in Xyrem. That drug is already approved as a sleep disorder treatment.
The company expects to ask the Food and Drug Administration to approve the drug as a fibromyalgia treatment by the and of 2009. Fibromyalgia is a pain disorder.
Jazz shares surged $1.50, or 46 percent, to $4.75 in morning trading. The stock has traded between 52 cents and $8.95 over the last 52 weeks.
52wk Range: 0.52 - 8.85
Volume: 14,934,014
Avg Vol (3m): 1,346,530
Technicals
Most Actives
Gap Up
Percentage Gainer
Last Price Quote is:
51.34%above 13-day MA
148.73%above 50-day MA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $100.95
P/E Ratio: N/A
PEG Ratio: N/A
Next Earnings: 08/06/2009
Last Analyst Rating: Sell
updated chart look... ;) ;D
52wk Range: 0.52 - 8.85
Volume: 8,953,648
Avg Vol (3m): 1,968,190
Technicals
Most Actives
Percentage Gainer
Last Price Quote is:
42.79%above 13-day MA
96.15%above 50-day MA
RS Rating: 99
Fundamentals
Earnings Expected on Aug 6
Key Data:
Market Cap (M): $127.35
P/E Ratio: N/A
PEG Ratio: N/A
Next Earnings: 08/06/2009
Last Analyst Rating: Underweight
updated chart look...
Jazz's fibromyalgia drug delivered promising preliminary late-stage data helped fueled a rapid rise in stock prices.
After trading up from $0.55...
The company confirmed the positive results from the first Phase III placebo-controlled trial of sodium oxybate. The treatment for fibromyalgia achieved its key endpoints. Only preliminary top-line efficacy and safety data are available at this time and further analyses are planned -- including analyses of additional secondary endpoints. JAZZ expects to submit a NDA for sodium oxybate to the FDA by the end of 2009.
52wk Range: 0.52 - 8.10
Volume: 1,762,037
Avg Vol (3m): 2,878,300
Technicals
Percentage Gainer
Last Price Quote is:
11.07%above 13-day MA
41.85%above 50-day MA
RS Rating: 99
Fundamentals
Key Data:
Market Cap (M): $194.50
P/E Ratio: N/A
PEG Ratio: N/A
Next Earnings: 11/05/2009
Last Analyst Rating: Underweight
;D
Updated chart look...
The 1 year chart below ;)
Jazz Pharma rockets on 3Q results, higher outlook
Jazz Pharma stock ends strong week by setting 9-year high after posting 3rd quarter results
On Friday November 5, 2010, 1:34 pm EDT
NEW YORK (AP) -- Shares of Jazz Pharmaceuticals Inc. rose to a nine-year high Friday, capping a weeklong rally after the company reported strong third-quarter results and raised its annual forecasts.
Jazz said its sales improved after it raised the price of its narcolepsy drug Xyrem, which is expected to boost its sales for the rest of the year. Its shares advanced to their highest prices since early 2001.
The Palo Alto, Calif., company reported a profit of $13.2 million, or 32 cents per share, in the third quarter. A year ago the company lost $1.7 million, or 5 cents per share, during the same period. Excluding one-time costs Jazz said its profit totaled 41 cents per share. Revenue rose 45 percent, to $44.8 million from $30.8 million.
Analysts expected a profit of 34 cents per share and revenue of $42.6 million on average, according to Thomson Reuters. Analyst estimates usually leave out one-time items. Shares of Jazz rose $1.75, or 14.1 percent, to $14.15 in afternoon trading.
Jazz markets Xyrem for daytime sleepiness in patients who have narcolepsy, and also for cataplexy, a condition associated with narcolepsy that causes sudden and brief losses of muscle control. Its other approved drug, Luvox CR, is a treatment for obsessive compulsive disorder and social anxiety disorder. The company said Xyrem revenue grew 49 percent to $37.2 million, mostly because of the increased price. Luvox sales rose to $6.6 million from $5 million. Jazz also reported $915,000 in revenue from royalties and contracts.
The company raised its profit and revenue forecasts because it expects more revenue from Xyrem, along with slightly lower research and development costs. Jazz is now forecasting a profit of $1.45 to $1.50 per share excluding one-time costs, up from $1.05 to $1.15 per share. It now expects sales of $164 million to $168 million in sales this year, compared with an earlier estimate of $156 million to $162 million.
Analysts were expecting a profit of $1.15 per share and $161.7 million in revenue.
Jazz is now projecting $140 million to $142 million from Xyrem rather than $132 million to $136 million. It still expects $24 million to $26 million in Luvox revenue.
Shares of Jazz Pharmaceuticals slumped in August after a Food and Drug Administration panel recommended against granting a new approval to Xyrem. Jazz wants to market the drug as a treatment for fibromyalgia, but the panel -- and later, the FDA itself -- said the drug's abuse risks were too great. The stock fell 22 percent the day after the panel made its recommendation.
Over the last four days, however, Jazz shares are up 16.7 percent. On Friday the stock set a high of $14.28.
Jazz Pharma rockets on 3Q results, higher outlook... ;) :D ;D
ends strong week by setting 9-year high after posting 3rd quarter results.
•Jazz Pharmaceuticals Announces Adjusted Net Income for the Third Quarter of $0.41 per Share and GAAP Net Income of $0.32 per Share
Day's Range: 13.55 - 14.83
52wk Range: 6.38 - 14.83
Volume: 3,426,842
Avg Vol (3m): 985,515
Technicals
Record Price High............... ;D
Gap Up
Percentage Gainer
Last Price Quote is:
28.12%above 13-day MA
38.25%above 50-day MA
RS Rating: 95
Below are the 6 month, 1 year, 2 year and 3 year charts.......
Jazz Pharma rally continues... 8)
Jazz Pharmaceuticals Inc. stock is up more than 30 percent this week, posting another double-digit gain on Friday after a strong earnings report the day before.
Palo Alto-based Jazz (NASDAQ:JAZZ) on Thursday reported third-quarter net income of $13.2 million, or 32 cents a share, compared to a loss in the same period last year of $1.7 million, or 5 cents a share.
Total revenue was $44.8 million, up 45 percent compared to the year-ago quarter.
The company also boosted its 2010 sales forecast to between $164 million and $168 million. It said earnings per share should be between 70 cents and 75 cents, with adjusted earnings between $1.45 and $1.50.
The boost is attributed to increased sales of the drug Xyrem, whose net sales in Q3 were $37.2 million, compared to $25 million for the third quarter of 2009.
Once-daily Luvox CR sales were also up 33 percent, bringing in $6.6 million in revenue.
Jazz closed the day Friday at $14.28, up from last Friday's closing price of $10.63.
Financials...awesome! ;)
Recent 52-Week High Exceeded in Shares of Jazz Pharmaceuticals (JAZZ)
Shares of Jazz Pharmaceuticals (JAZZ) traded near a new 52-week high yesterday of $15.32. Approximately 1.7 million shares traded hands 11/09/2010 vs. average 30-day volume of 656,000 shares.
Jazz Pharmaceuticals closed at $14.97, approximately 4.8% above its previous closing price. Will be monitoring shares of JAZZ to see if it can push through this barrier.
Day's Range: 14.77 - 15.23
52wk Range: 6.38 - 15.32
Volume: 447,662
Avg Vol (3m): 1,049,130
Market Cap: 584.77
Technicals
Last Price Quote is:
13.46%above 13-day MA
32.74%above 50-day MA
RS Rating: 91
Jazz Pharmaceuticals continues to rebound from it's failure to get its Xyrem approved in fibromyalgia based on better financial outlook based in part on price increases for the drug. HeartWare rose on an analysis presented at the annual meeting of the American Heart Association that showed its device for helping the hearts of transplant patients pump may outperform that of rival Thoratec, which was one of the biggest decliners.
Day's Range: 17.84 - 19.08
52wk Range: 6.38 - 19.08
Volume: 1,027,968
Avg Vol (3m): 703,939
Market Cap: 722.71M
P/E (ttm): 48.49
EPS (ttm): 0.38
Div & Yield: N/A (N/A
Technicals
Record Price High
Last Price Quote is:
10.19%above 13-day EMA
33.77%above 50-day EMA
RS Rating: 97
Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate
Press Release Source: Jazz Pharmaceuticals, Inc. On Tuesday December 21, 2010, 4:05 pm EST
PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ - News) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem® (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy." The new patent, number 7,851,506, is also listed in the FDA's Approved Drug Products List (the Orange Book).
In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product's formulation and Jazz Pharmaceuticals' distribution system. Six issued patents are now listed in the Orange Book. These patents expire from 2019 to 2024.
"Enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, Jazz Pharmaceuticals' intent to vigorously enforce its intellectual property rights. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to protect its intellectual property and defend its patents, the possible introduction of generic products, the dependence of the company on sales of Xyrem, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 5, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
Jazz Pharmaceuticals: When Is FDA Rejection a Good Thing?
December 20, 2010
By Alexander Moschina
It wasn't exactly the way that California-based Jazz Pharmaceuticals (Nasdaq: JAZZ) wanted to start the week.
On Monday, October 11, word came through from the Food & Drug Administration that it had rejected the company's fibromyalgia treatment called JZP-6.
The reason? Turns out it contains sodium oxybate – an active ingredient in GHB, also known as "the date rape drug."
But then a funny thing happened. Rather than Jazz shares getting clobbered (as you'd ordinarily expect after such news), the stock began to climb. From a closing price of $10.51 on October 11, the stock now sits at $19.08 (as of December 20) – a remarkable 81% gain, which included a 52-week high of $19.41 on December 17.
In addition, Jazz's third quarter earnings results led the company to raise its full-year profit forecast by 38% to $1.45 – $1.50 per share.
Year-to-date, Jazz shares are up a whopping 142%. And going into 2011, this drug manufacturer shows no sign of slowing down...
Two Drugs... A 79% Combined Sales Jump – And Just a Taste of Things to Come...
Breaking down Jazz's third quarter results, the company notched up total revenue of $44.8 million – a 45% jump over the $30.8 million during Q3 2009. The increase came as it saw a significant sales rise for two of its major drugs...
•Luvox: The anti-depressant, used to treat Obsessive Compulsive Disorder, brought in $6.6 million for the quarter. Year-over-year, sales of the drug have increased more than 30%.
•Xyrem: This drug is taken to prevent cataplexy attacks (episodes of muscle weakness) in patients with narcolepsy. It raked in $37.2 million for the quarter – a 49% increase over 3Q 2009. But this treatment will soon yield even bigger profits...
Jazz Shares Are Flying... With Rising Sales and Prices Set to Fire Shares in 2011
Any day now, Jazz will raise the price of Xyrem by as much as 22%. And considering that the drug makes up more than three-quarters of the company's total revenue, the hike is guaranteed to send 2011 profits soaring.
According to Jazz co-founder and President Robert Myers, "We could more than double that current price and still be below [the price] ceiling."
And as prices go up, research and development costs are plummeting, making way for huge profit margins. During the third quarter of 2009, R&D expenses totaled $7.6 million, but in the same period this year, they fell to $7.3 million. Overall, costs have dropped by more than 40% this year.
So even though the FDA rejected Jazz's fibromyalgia treatment, that's not enough to squash this up-and-coming biotech. Unlike other one-trick companies, Jazz already boasts two major products with sales rising. Plus, it's now cheaper for the company to develop the items in its pipeline.
In a recent conference call, CEO Bruce Cozadd described 2010 as a "pivotal" year for the company. And thanks to the strong momentum Jazz has built, 2011 is shaping up to be even bigger.
Disclosure: Investment U expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees and agents of Investment U (and affiliated companies) must wait 24 hours after an initial trade recommendation is published on online - or 72 hours after a direct mail publication is sent - before acting on that recommendation.
Disclaimer: The Oxford Club LLC/Investment U and Stansberry & Associates Investment Research are separate companies, and entirely distinct. Their only common thread is a shared parent company, Agora Inc. Agora Inc. was named in the suit by the SEC and was exonerated by the court, and thus dropped from the case. Stansberry & Associates was found civilly liable for a matter that dealt with one writer's report on a company. The action was not a criminal matter.
Quote from: setravis on December 06, 2010, 11:22:56 PM
Jazz Pharmaceuticals continues to rebound from it's failure to get its Xyrem approved in fibromyalgia based on better financial outlook based in part on price increases for the drug. HeartWare rose on an analysis presented at the annual meeting of the American Heart Association that showed its device for helping the hearts of transplant patients pump may outperform that of rival Thoratec, which was one of the biggest decliners.
Jazz Hits High Note...
On the upside, Jazz Pharmaceuticals (JAZZ) jumped 4% in fast trade, clearing a 24.07 buy point from a square-box base. The 2007 IPO, featured in a New America article on Jan. 20, gets the lion's share of its revenue from Xyrem, a drug that treats narcolepsy. Jazz posted a string of quarterly losses through early 2009, but turned profitable in the second half of that year. EPS surged 583% in the latest quarter.
Day's Range: 23.15 - 25.23
52wk Range: 6.38 - 25.23
Volume: 1,551,183
Avg Vol (3m): 643,552
Market Cap: 942.59M
P/E (ttm): 62.91
EPS (ttm): 0.39
Div & Yield: N/A (N/A)
Technicals
Record Price High
Percentage Gainer
RS Rating: 95
Ascending Triangle (continuation) Pattern...
Jazz Pharmaceuticals, Inc. (JAZZ)...
recently spiked to a new multi-year high on the company's third consecutive earnings surprise. With estimates on the rise and a bullish growth projection, stock sings in the key of momentum.
Jazz specializes in developing products for neurology and psychiatry primarily in the United States. The company was founded in 2003 and has a market cap of $1.12 billion.
Although JAZZ has been trending higher since early November, shares got an extra boost on March 7 after the company reported strong Q4 results that came in ahead of expectations.
Fourth-Quarter Results
Revenue for the period was up 39% from last year to $53.4 million. Earnings also looked good, coming in at 56 cents, 4% ahead of the Zacks Consensus Estimate, where the company has an average earnings surprise of 12% over the last three quarters.
The strong performance was led by the company's Xyrem, a narcolepsy and sleeping disorder drug, with sales up 36% from last year to $43 million. Full-year sales for Xyrem were up 47% from last year. Sales for its other leading product, Luvox, increased to $9.4 million from $5.7 million.
Financial Profile
With 2010 marking Jazz's first full year of profitability, the company's financial profile has been on the upswing. Cash and equivalents are up $16 million from last year to $45 million while total debt fell $76 million to $48 million.
Estimates
We saw some very bullish movement in estimates off the good quarter, with the current year adding 52 cents to $2.57 while the next-year estimate jumped $1.04 to $3.35, a bullish 30% growth projection.
Valuation
But in spite of the gains, the valuation picture still looks great, with a PEG ratio )PE/Growth) of .36%, well below the benchmark for value of 1.
12-Month Chart
On the chart, shares got a boost off the good quarter to hit a new multi-year high at $29.73. Take a look at the chart below.
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=50309)
;) Jazz Pharmaceuticals (Nasdaq: JAZZ ) , maker of narcolepsy drug Xylem and OCD drug Luvox, gained 143% over the past year as its revenue soared. ;D
Healthy Momentum...Breaking out above 30 today.
Day's Range: 30.00 - 32.34
52wk Range: 6.38 - 32.34
Volume: 988,624
Avg Vol (3m): 765,810
Market Cap: 1.30B
P/E (ttm): 38.80
EPS (ttm): 0.83
Div & Yield: N/A (N/A)
Technicals
Record Price High
Percentage Gainer
Last Price Quote is:
11.25%above 13-day EMA
26.85%above 50-day EMA
RS Rating: 95